Pharmaceuticals News 29 September 2025

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicines marketbeat.com astrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London

11 October 2025

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Metric Merck (MRK) Last Price (10/10/25) $86.02 marketbeat.com Market Cap $215B marketbeat.com P/E (TTM) ~13× marketbeat.com Yield 3.8% marketbeat.com 52-Week Range $73.31 – $111.58 marketbeat.com YTD Total Return -11.07% financecharts.com Q2 2025 Sales

11 October 2025

Drug Approvals · Financial News · Investment Analysis · NYSE:MRK · Pharmaceuticals · Stock Market

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its

11 October 2025

Biotech · Clinical Trials · Mergers & Acquisitions · Pharmaceuticals · Stock Market

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this

9 October 2025

Drug Development · Healthcare Industry · Liver Health · Medical Innovation · NASDAQ:AKRO · NYSE:NVO · Pharmaceuticals

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Current News & October 2025 Updates EMA Positive Opinion: A major recent catalyst for Acurx came on September 30, 2025, when the EMA’s Paediatric Committee issued a positive opinion on the Pediatric Investigation Plan (PIP) for

8 October 2025

Analyst Predictions · Investment Insights · Market Trends · NASDAQ:ACXP · Pharmaceuticals · Stock Analysis

Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Puerto Rico’s pharmaceutical roots and the Section 936 story For much of the late 20th century, Puerto Rico was an unlikely but critical component of America’s medicine chest. The island’s status as a U.S.

6 October 2025

Business Opportunities · Manufacturing · Pharmaceuticals · Puerto Rico Economy · Reshoring

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share

4 October 2025

Biotech · Investment Analysis · Market Trends · NASDAQ:CDTX · Pharmaceuticals · Stock Market · Stocks

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis

3 October 2025

Biotechnology · Healthcare · Investment News · NASDAQ:TARS · Pharmaceuticals · Stock Market

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day investing.com. This followed a general uptrend in recent

2 October 2025

Biotech · FDA Approvals · Gene Therapy · NASDAQ:SRPT · Pharmaceuticals · Stock Analysis · Stock Market

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx

30 September 2025

Healthcare · NYSE:PFE · Pharmaceuticals · Policy · Politics · US News

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64×

30 September 2025

Business News · NYSE:PFE · Pharmaceuticals · Stock Market · Stocks · Trump Administration · Weight Loss

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

Market Overview On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed

29 September 2025

European Markets · Investment Strategies · NYSE:AZN · NYSE:GSK · Pharmaceuticals · Stock Market · Technology

Pharmaceuticals News 29 September 2025 - 11 October 2025